On-Demand Bioresorbable OptoElectronic System for In-Vivo and In-Situ Monitoring of Chemotherapeutic Drugs
Develop a bioresorbable chemical sensing system for real-time monitoring of doxorubicin in-vivo, enhancing personalized cancer treatment while eliminating the need for device retrieval surgery.
Projectdetails
Introduction
We envision a radically new technology for in-vivo bioresorbable chemical sensing, where optical devices, power and light sources, synthetic receptors - made out of materials that completely dissolve with biologically benign byproducts in biofluids - will be developed and integrated together.
System Design
The sensing system, the size of 1 EuroCent, will be coated by a long-lived biocompatible polymer designed with on-demand degradation. It will then be implanted in the body to monitor in-vivo, in-situ, and in real-time a chemotherapeutic drug, doxorubicin, commonly used to treat cancer.
Dissolution Process
The system is then fully and safely RESORBed once no longer needed using an external temperature-trigger that initiates the dissolution of the protecting coating and, in turn, of the system. This process avoids device-retrieval surgery that may cause tissue lesion/infection.
Objectives
The general objective is to demonstrate:
- Fabrication
- Operation (2 months) in-vivo and in real-time
- Dissolution of such a bioresorbable chemical sensing system for the detection of doxorubicin in an animal model.
This will break new ground in in-situ monitoring of chemotherapeutic drugs, enabling for the first time a fine-tuning of the drug dose at the tumor site, thereby increasing patient survival rates.
Risk Management
Being aware of the project risks, we have broken down the general objectives into different specific objectives. We have identified a set of Key Performance Indicators, alternative material synthesis/device fabrication techniques, and mitigation measures to tackle major risks.
Future Implications
The RESORB technology truly represents the foundation of a future technology for personalized medicine. It enables addressing a number of medical issues for which continuous and localized monitoring of specific analytes (i.e., biomarkers and drugs) in-vivo for a prescribed time is of chief importance.
Examples of Applications
Examples include:
- Acute trauma treatment
- Post-surgery sepsis
- Drug therapeutic profiling
These are all cases for which ex-situ analysis of biofluids has proved to be not fully adequate for clinical needs.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.606.250 |
Totale projectbegroting | € 2.606.250 |
Tijdlijn
Startdatum | 1-4-2022 |
Einddatum | 30-9-2025 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- UNIVERSITA DI PISApenvoerder
- INSTITUT MINES-TELECOM
- UNIVERSITA DEL SALENTO
- INSTITUTO DE TELECOMUNICACOES
- UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA
- UNIVERSITY COLLEGE LONDON
- LIBERA UNIVERSITA DI BOLZANO
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Bioorthogonal Implantable Iontronic Switch to Temporally Control the Local Release of ChemotherapeuticsThe project aims to develop an implantable bioSWITCH for on-demand drug delivery to tumors, enhancing treatment efficacy and survival rates in pancreatic cancer. | EIC Pathfinder | € 4.420.511 | 2023 | Details |
In-vessel implantable smart sensing device for personalised medicineThe IV-Lab project develops a miniaturized implantable sensor for continuous health monitoring in cardiovascular patients, enabling personalized medical interventions and reducing hospitalizations. | EIC Pathfinder | € 4.158.610 | 2023 | Details |
Personalised Adaptive MedicineThe PERAMEDIC project aims to develop a desktop-sized system for personalized polypill formulation using 3D printing and precise dosing to enhance treatment outcomes and patient adherence. | EIC Pathfinder | € 1.726.876 | 2024 | Details |
ISOS-Implantable Ecosystems of Genetically Modified Bacteria for the Personalized Treatment of Patients with Chronic DiseasesISOS aims to create a personalized bioreactor using engineered probiotics for on-demand delivery of therapeutic compounds to treat chronic diseases like age-related macular degeneration. | EIC Pathfinder | € 2.433.300 | 2023 | Details |
Live Cell Spectroscopy Analysis for Personalised Particle Radiation Therapy of Metastatic Bone CancerBoneOscopy aims to revolutionize metastatic bone cancer treatment by enabling daily monitoring during particle radiotherapy, enhancing personalized care and treatment efficacy. | EIC Pathfinder | € 3.069.321 | 2025 | Details |
Bioorthogonal Implantable Iontronic Switch to Temporally Control the Local Release of Chemotherapeutics
The project aims to develop an implantable bioSWITCH for on-demand drug delivery to tumors, enhancing treatment efficacy and survival rates in pancreatic cancer.
In-vessel implantable smart sensing device for personalised medicine
The IV-Lab project develops a miniaturized implantable sensor for continuous health monitoring in cardiovascular patients, enabling personalized medical interventions and reducing hospitalizations.
Personalised Adaptive Medicine
The PERAMEDIC project aims to develop a desktop-sized system for personalized polypill formulation using 3D printing and precise dosing to enhance treatment outcomes and patient adherence.
ISOS-Implantable Ecosystems of Genetically Modified Bacteria for the Personalized Treatment of Patients with Chronic Diseases
ISOS aims to create a personalized bioreactor using engineered probiotics for on-demand delivery of therapeutic compounds to treat chronic diseases like age-related macular degeneration.
Live Cell Spectroscopy Analysis for Personalised Particle Radiation Therapy of Metastatic Bone Cancer
BoneOscopy aims to revolutionize metastatic bone cancer treatment by enabling daily monitoring during particle radiotherapy, enhancing personalized care and treatment efficacy.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Implantable sensors and ultrasonic data link with triggered bioresorption for next-gen wireless cardiac monitoringThe 2ND-CHANCE project aims to develop bioresorbable implants for continuous cardiac monitoring post-surgery, reducing rehospitalization risks and eliminating the need for removal surgery. | ERC Starting... | € 2.500.000 | 2022 | Details |
Biomimetic Sensorized Barriers-on-a-Chip: Unveiling a new Generation of Market-Ready Investigation ToolsThis project aims to validate a novel, dynamic blood-brain barrier model with sensing features for improved drug screening in CNS pathologies, reducing reliance on animal testing and clinical trial failures. | ERC Proof of... | € 150.000 | 2024 | Details |
Bioorthogonal Iontronic Chemistry: Spatiotemporal Drug Release with Electronic PrecisionDevelop a programmable drug delivery system using Biontronic Chemistry for precise spatiotemporal release, enhancing treatment efficacy while minimizing side effects in various therapies. | ERC Starting... | € 1.496.795 | 2024 | Details |
Multifunctional Platform Technology for Magnetically Actuated Controlled Drug Release from Biodegradable ScaffoldsMAD Control aims to develop a multifunctional platform for biodegradable cardiovascular scaffolds that enables precise, on-demand drug release through real-time imaging and magnetic actuation. | ERC Starting... | € 1.495.288 | 2024 | Details |
Neuromorphic Flexible Electro/chemical Interface for in-Memory Bio-Sensing and Computing.Develop a miniaturized, self-contained biosensing technology using neuromorphic devices for real-time monitoring and classification of neurodegenerative biomarkers in individualized healthcare. | ERC Starting... | € 1.500.000 | 2025 | Details |
Implantable sensors and ultrasonic data link with triggered bioresorption for next-gen wireless cardiac monitoring
The 2ND-CHANCE project aims to develop bioresorbable implants for continuous cardiac monitoring post-surgery, reducing rehospitalization risks and eliminating the need for removal surgery.
Biomimetic Sensorized Barriers-on-a-Chip: Unveiling a new Generation of Market-Ready Investigation Tools
This project aims to validate a novel, dynamic blood-brain barrier model with sensing features for improved drug screening in CNS pathologies, reducing reliance on animal testing and clinical trial failures.
Bioorthogonal Iontronic Chemistry: Spatiotemporal Drug Release with Electronic Precision
Develop a programmable drug delivery system using Biontronic Chemistry for precise spatiotemporal release, enhancing treatment efficacy while minimizing side effects in various therapies.
Multifunctional Platform Technology for Magnetically Actuated Controlled Drug Release from Biodegradable Scaffolds
MAD Control aims to develop a multifunctional platform for biodegradable cardiovascular scaffolds that enables precise, on-demand drug release through real-time imaging and magnetic actuation.
Neuromorphic Flexible Electro/chemical Interface for in-Memory Bio-Sensing and Computing.
Develop a miniaturized, self-contained biosensing technology using neuromorphic devices for real-time monitoring and classification of neurodegenerative biomarkers in individualized healthcare.